NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, Forecast & News

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced its quarterly earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported $1.23 EPS for the quarter, missing analysts' consensus estimates of $1.43 by $0.20. The specialty pharmaceutical company had revenue of $51.30 million for the quarter, compared to the consensus estimate of $56.10 million. ANI Pharmaceuticals had a return on equity of 28.28% and a net margin of 7.58%. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.29 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for ANI Pharmaceuticals.

ANI Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Tuesday, December, 3rd. The company provided earnings per share (EPS) guidance of 5.06-5.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.14. The company issued revenue guidance of $209-212 million, compared to the consensus revenue estimate of $209.67 million.

4 brokerages have issued twelve-month target prices for ANI Pharmaceuticals' stock. Their forecasts range from $76.00 to $90.00. On average, they expect ANI Pharmaceuticals' share price to reach $84.25 in the next year. This suggests a possible upside of 38.4% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

Headlines about ANIP stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for ANI Pharmaceuticals.

ANI Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 705,700 shares, a decrease of 5.6% from the December 15th total of 747,900 shares. Based on an average trading volume of 168,500 shares, the short-interest ratio is presently 4.2 days. Currently, 7.5% of the company's stock are short sold. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include Axsome Therapeutics (AXSM), Genmab A/S (GMAB), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Alkermes (ALKS), Uniqure (QURE), ArQule (ARQL), ChemoCentryx (CCXI), Karuna Therapeutics (KRTX), Zogenix (ZGNX), Amicus Therapeutics (FOLD), Ra Pharmaceuticals (RARX), Synthorx (THOR), Arena Pharmaceuticals (ARNA) and Aurinia Pharmaceuticals (AUPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Broadcom (AVGO), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Cisco Systems (CSCO), NVIDIA (NVDA), NXP Semiconductors (NXPI) and Skyworks Solutions (SWKS).

ANI Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virginia Retirement Systems ET AL (0.10%), Strs Ohio (0.09%), Rothschild Investment Corp IL (0.08%), Nisa Investment Advisors LLC (0.06%), Arizona State Retirement System (0.05%) and Mesirow Financial Investment Management Inc. (0.05%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System and Mesirow Financial Investment Management Inc.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

ANIP stock was acquired by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL, Nisa Investment Advisors LLC, Virginia Retirement Systems ET AL, Strs Ohio and Wedge Capital Management L L P NC. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $60.87.

ANI Pharmaceuticals has a market capitalization of $735.92 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]